PGI2 inhibits ischemia-induced platelet activation and prevents myocardial damage by inhibition of catecholamine release from adrenergic nerve terminals. Evidence for cAMP as common denominator.
D000320:Adrenergic Fibers / Q000378:metabolism; D000818:Animals; D001095:Arachidonic Acids / Q000494:pharmacology; D001792:Blood Platelets / Q000503:physiopathology*; D002395:Catecholamines / Q000378:metabolism; D002415:Cats; D003285:Contractile Proteins / Q000494:pharmacology; D003327:Coronary Disease / Q000209:etiology*; D000242:Cyclic AMP / Q000378:metabolism; D011464:Epoprostenol / Q000494:pharmacology*; D005260:Female; D008297:Male; D009206:Myocardium / Q000473:pathology*; D011453:Prostaglandins / Q000494:pharmacology*; D011817:Rabbits
D001095:Arachidonic Acids; D002395:Catecholamines; D003285:Contractile Proteins; D011453:Prostaglandins; D011464:Epoprostenol; D000242:Cyclic AMP